The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 284-292

  Kim, Myung Jin ^a   Lee, Jong Ho ^a   Kim, Young Kyun ^b   Myoung, Hoon ^a   Yun, Pil Young ^b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Apoptosis; Cisplatin; Oral squamous cell carcinoma; Tamoxifen

Indexed keywords

CISPLATIN; ESTROGEN RECEPTOR; PROTEIN KINASE C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; EVALUATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; MOUTH NEOPLASMS; PROTEIN KINASE C; RECEPTORS, ESTROGEN; TAMOXIFEN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33845788136     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.017     Document Type: Article

References (42)

1. Forastiere A.A., Metch B., Schuller D.E., Ensley J.F., Hutchins L.F., Triozzi P., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 10 (1992) 1245-1251
2. Cohen S.M., and Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67 (2001) 93-130
3. Tanaka T., Masuda H., Naito M., and Tamai H. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Anticancer Res. 21 (2001) 2463-2469
4. McClay E.F., McClay M.T., Monroe L., Jones J.A., and Winski P.J. A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res. 11 (2001) 309-313
5. Mandlekar S., and Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 (2001) 469-477
6. Aldous W.K., Marean A.J., DeHart M.J., Matej L.A., and Moore K.H. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer 85 (1999) 1523-1529
7. Rusthoven J.J. The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Eur. J. Cancer 34 (1998) S31-S36
8. McClay E.F., McClay M.E., Monroe L., Baron P.L., Cole D.J., O'Brien P.H., et al. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br. J. Cancer 83 (2000) 16-21
9. Lin C.C., Hsu C.H., Chen J., Tsai T.C., Cheng A.L., and Pu Y.S. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res. 21 (2001) 1385-1390
10. Hsu C.H., Chen J., Wu C.Y., Cheng A.L., and Pu Y.S. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 21 (2001) 711-715
11. Chen Y., Perng R.P., Yang K.Y., Lin W.C., Wu H.W., Tsai C.M., et al. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer 29 (2000) 139-146
12. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., and van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84 (1994) 1415-1420
13. Scanlon K.J., Kashani-Sabet M., Tone T., and Funato T. Cisplatin resistance in human cancers. Pharmacol. Ther. 52 (1991) 385-406
14. McClay E.F., Albright K.D., Jones J.A., Eastman A., Christen R., and Howell S.B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 52 (1992) 6790-6796
15. Kern M.A., Helmbach H., Artuc M., Karmann D., Jurgovsky K., and Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res. 17 (1997) 4359-4370
16. Kuo N.T., Agani F.H., Haxhiu M.A., and Chang C.H. A possible role for protein kinase C in CO2/H+-induced c-fos mRNA expression in PC12 cells. Respir. Physiol. 111 (1998) 127-135
17. Tan C.K., Chow P.K., Findlay M., Wong C., and Machin D. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. J. Gastroenterol. Hepatol. 15 (2000) 725-729
18. Pu Y.S., Hsieh T.S., Tsai T.C., Cheng A.L., Hsieh C.Y., Su I.J., et al. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J. Urol. 154 (1995) 601-605
19. Lara Jr. P.N., Gandara D.R., Wurz G.T., Lau D., Uhrich M., Turrell C., et al. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother. Pharmacol. 42 (1998) 504-508
20. Otto A.M., Paddenberg R., Schubert S., and Mannherz H.G. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J. Cancer Res. Clin. Oncol. 122 (1996) 603-612
21. Perry R.R., Kang Y., and Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol. 2 (1995) 238-245
22. Obrero M., Yu D.V., and Shapiro D.J. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J. Biol. Chem. 277 (2002) 45695-45703
23. MacGregor J.I., and Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50 (1998) 151-196
24. Webb P., Lopez G.N., Uht R.M., and Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9 (1995) 443-456
25. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
26. Hall J.M., and McDonnell D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 (1999) 5566-5578
27. Struse K., Audretsch W., Rezai M., Pott G., and Bojar H. The estrogen receptor paradox in breast cancer: association of high receptor concentrations with reduced overall survival. Breast J. 6 (2000) 115-125
28. Grenman R., Virolainen E., Shapira A., and Carey T. In vitro effects of tamoxifen on UM-SCC head and neck cancer cell lines: correlation with the estrogen and progesterone receptor content. Int. J. Cancer 39 (1987) 77-81
29. Blackwell K.L., Haroon Z.A., Shan S., Saito W., Broadwater G., Greenberg C.S., et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin. Cancer Res. 6 (2000) 4359-4364
30. O'Brian C.A., Liskamp R.M., Solomon D.H., and Weinstein I.B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 45 (1985) 2462-2465
31. Cheng A.L., Chuang S.E., Fine R.L., Yeh K.H., Liao C.M., Lay J.D., et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem. Pharmacol. 55 (1998) 523-531
32. Horgan K., Cooke E., Hallett M.B., and Mansel R.E. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem. Pharmacol. 35 (1986) 4463-4465
33. Hoelting T., Duh Q.Y., Clark O.H., and Herfarth C. Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C. Cancer Lett. 100 (1996) 89-93
34. Ahn S.J., Yoon M.S., Hyuk S., Han W., Yoon Y.D., Han J.S., et al. Phospholipase C-protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis. J. Cell. Biochem. 89 (2003) 520-528
35. Couldwell W.T., Hinton D.R., He S., Chen T.C., Sebat I., Weiss M.H., et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. Fed. Eur. Biochem. Soc. Lett. 345 (1994) 43-46
36. Pouliot F., and Labrie C. Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens. Int. J. Cancer 81 (1999) 98-103
37. Perry R.R., Kang Y., and Greaves B.R. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br. J. Cancer 72 (1995) 1441-1446
38. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29 (2001) 117-129
39. Iacopetta B.J., Welch J., Soong R., House A.K., Zhou X.P., and Hamelin R. Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: relationship to clinicopathological features and genetic alterations. J. Pathol. 184 (1998) 390-395
40. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 67 (1998) 753-791
41. Yamamoto T., Saatcioglu F., and Matsuda T. Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 143 (2002) 2635-2642
42. Stoica A., Saceda M., Fakhro A., Solomon H.B., Fenster B.D., and Martin M.B. The role of transforming growth factor-beta in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology 138 (1997) 1498-1505